<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04011280</url>
  </required_header>
  <id_info>
    <org_study_id>180785</org_study_id>
    <nct_id>NCT04011280</nct_id>
  </id_info>
  <brief_title>Novel Pharmacotherapy Approaches in Smokers With Serious Mental Illness</brief_title>
  <official_title>Novel Pharmacotherapy Approaches in Smokers With Serious Mental Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Veterans Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 60 chronic smokers with bipolar disorder, schizophrenia or schizoaffective&#xD;
      disorder who are motivated to try to quit smoking will be randomized to receive smoking&#xD;
      cessation treatment with the FDA-approved medication, varenicline, delivered either a) at its&#xD;
      standard dose and titration schedule (half of the participants) versus b) at a lower dose and&#xD;
      slower titration schedule (the other half), for 12 weeks. All smokers will choose a target&#xD;
      quit date sometime between 8 to 35 days after starting the medication. All participants will&#xD;
      receive ten 30-minute sessions of a behavioral treatment called Acceptance and Commitment&#xD;
      Therapy (ACT). Participants will be followed for an additional 12 weeks off study medication.&#xD;
      The major endpoint is the feasibility of combining ACT with the different dosing strategies.&#xD;
      Investigators will also conduct a blood test that measures the breakdown of nicotine in the&#xD;
      body to explore whether that measure influences treatment response and side effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot feasibility trial is a Phase IV, 12-week, single center, randomized, double blind,&#xD;
      parallel group comparison of low (0.5 mg twice daily with slower titration over one full&#xD;
      week) versus standard dose (1.0 mg twice daily with standard titration) varenicline in&#xD;
      individuals with DSM-V Bipolar Disorder (BD) or Schizophrenia Spectrum Disorders (SSD) with a&#xD;
      12-week, post-treatment follow-up. The 16 visits after screening (Weeks 0-24) include 11&#xD;
      in-person (with medications dispensed at weeks 0, 2, 4, 6, 8 and 10] and 5 via telephone.&#xD;
      Plasma will be obtained at baseline to measure participants' Nicotine Metabolite Ratio (NMR)&#xD;
      and to identify slow versus normal nicotine metabolisers. A flexible quit date (between days&#xD;
      8-35) will be employed allowing varenicline preloading to occur prior to the Target Quit&#xD;
      Date. Ten sessions of Acceptance &amp; Commitment Therapy (ACT) for smoking cessation will be&#xD;
      delivered by trained counselors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This pilot trial is a Phase IV, 12-week, single center, randomized, double blind, parallel group comparison of low (0.5 mg twice daily with slower titration over one full week) versus standard dose (1.0 mg twice daily with standard titration) varenicline in individuals with DSM-V BD or SSD with a 12-week, post-treatment follow-up.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Everyone, with the exception of the study pharmacist, will be blinded to which arm participants will be randomized into.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of combining ACT with 2 different varenicline-assisted quitting strategies</measure>
    <time_frame>Through completion of study, an average of 2 years</time_frame>
    <description>Demand for participating (# of participants recruited per month); practicality of study procedures (% participants completing study procedures); acceptability of study procedures (% participants adhering to making a quit attempt within the quit window)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Explore whether nicotine metabolism influences medication tolerability</measure>
    <time_frame>Through completion of study, an average of 2 years</time_frame>
    <description>Nicotine metabolite ratio (ratio of trans-3'-hydroxycotinine / cotinine in plasma) in relation to adverse events (volunteered, observed or solicited adverse events occurring during study treatment + 30 days). Slow nicotine metabolisers will be compared with normal nicotine metabolisers on the incidence (% who experienced) adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>Low Dose Varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg twice daily with 0.5 mg daily titration over one full week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Dose Varenicline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.0 mg twice daily with standard titration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>The ten 30-minute sessions will target core processes in ACT such as acceptance and being present.</description>
    <arm_group_label>Low Dose Varenicline</arm_group_label>
    <arm_group_label>Standard Dose Varenicline</arm_group_label>
    <other_name>Acceptance and Commitment Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-70 years of age&#xD;
&#xD;
          -  Outpatients with a DSM-V diagnosis of Bipolar Disorder or Schizophrenia Spectrum&#xD;
             Disorder&#xD;
&#xD;
          -  Smoke at least 10 cigarettes per day and have an expired carbon monoxide (CO)&#xD;
             breathalyzer of â‰¥ 10 ppm at screening and baseline visits&#xD;
&#xD;
          -  Are motivated to quit smoking&#xD;
&#xD;
          -  Have access to a mental health provider&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females who are pregnant, planning to become pregnant, or lactating&#xD;
&#xD;
          -  Test positive for any non-prescribed medications or illicit drugs&#xD;
&#xD;
          -  Have made a suicide attempt or engaged in self-mutilatory behavior in the past year&#xD;
&#xD;
          -  Meet criteria for another Substance Use Disorder in the past month&#xD;
&#xD;
          -  In the investigators' judgement, are either psychiatrically or medically unstable to&#xD;
             safely participate&#xD;
&#xD;
          -  Are currently using any other form of treatment for smoking cessation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Benjamin McKenna, PhD</last_name>
    <phone>858-534-8817</phone>
    <email>bmckenna@ucsd.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pacific Treatment &amp; Research Center at UCSD</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert M Anthenelli, MD</last_name>
      <phone>858-246-4673</phone>
      <email>PacTarc@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ben McKenna, PhD</last_name>
      <phone>858-246-4673</phone>
      <email>PacTarc@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Robert Anthenelli, MD</investigator_full_name>
    <investigator_title>Principal Investigator and Study Physician</investigator_title>
  </responsible_party>
  <keyword>nicotine</keyword>
  <keyword>varenicline</keyword>
  <keyword>Acceptance and Commitment Therapy</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>schizoaffective</keyword>
  <keyword>bipolar</keyword>
  <keyword>smoking cessation</keyword>
  <keyword>cigarette</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

